德琪医药-B：ATG-022联合KEYTRUDA (帕博利珠单抗)±化疗的IB/II期研究于中国获授予IND批准
ANTENGENEANTENGENE(HK:06996) Zhi Tong Cai Jing·2025-12-02 08:52

Core Viewpoint - The approval of the investigational new drug (IND) application for ATG-022, a CLDN18.2 antibody-drug conjugate, in combination with MSD's KEYTRUDA and chemotherapy, marks a significant advancement in cancer treatment options [1] Group 1 - The National Medical Products Administration of China has approved the IND application for ATG-022 [1] - The approval includes the evaluation of ATG-022 in combination with KEYTRUDA and chemotherapy in the Ib/II phase CLINCH-2 study [1]